3T Biosciences

We're hiring: https://lnkd.in/g_ECZWJj #proteinsciences #scientistII #seniorscientist

Congratulations to our co-founder, Chris Garcia, Ph.D., on receiving Emory Max Cooper Prize in Immunology! This prestigious award recognizes Dr. Garcia’s exceptional contributions to the field of immunology that continue to shape the future of our field. His dedication and innovative spirit are at the heart of 3T Biosciences’ mission of developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations. Please join us in celebrating this well-deserved recognition of Chris’s remarkable work and commitment to scientific excellence. #ProudMoment #Immunology #3TBiosciences #Innovation #Leadership #Healthcare https://lnkd.in/enjgYhrG

We're #Hiring! #proteinsciences #scientistII #seniorscientist

🎉 Congratulations to Christopher Garcia, Ph.D., on being named the 2024 Passano Award winner! 🎉 3T Biosciences was founded on the work of Dr. Garcia. His pioneering research has unveiled critical insights into T-cell receptor structure, recognition of peptide-HLA, T-cell signaling and the identification of tumor antigens, leading to the development of innovative proteins with the potential for safer and more effective cancer therapies. It’s inspiring to see over a half-dozen engineered proteins from his lab now undergoing clinical trials, bringing hope and advancements to patients worldwide. Congratulations, Dr. Garcia, on this prestigious honor! #ScienceExcellence #PassanoAward #CancerResearch #Innovation #3TBiosciences #Immunotherapy

We are excited to share groundbreaking research from our Chief Development Officer Estelle Marrer-Berger, Ph.D., that was recently published in Nature Communications. The study, based on research conducted while at Roche, sheds light on the intricate interplay between novel TCR-like antibody therapeutics and human tissue environments, unlocking crucial insights that pave the way for enhanced efficacy and safety in therapeutic interventions. You can read Estelle’s paper, titled “The physiological interactome of TCR-like antibody therapeutics in human tissues,” here: https://lnkd.in/eSGfSV78 Huge congratulations to Dr. Marrer-Berger and the entire team for this remarkable achievement! This reinforces 3 T’s commitment to using great science to develop immunotherapies that dramatically improve treatments for patients in need. #BioTech #Immunotherapy #Roche #NatureCommunications

We are excited to announce 3T Biosciences will be participating at MassBio 2024 Align Summit with insights by McKinsey & Company and Locust Walk. If you would like to hear our presentation, please register here: https://lnkd.in/gvm4wtay   #AlignSummit24 #AlignSummit #AIDrugDiscovery 

3T Biosciences is excited to announce the creation of a transatlantic pan-#CancerResearch pipeline in collaboration with decorated academic investigators at University of Oxford , VIB, KU Leuven , and University of California, San Francisco. These research partnerships aim to identify novel targets in the most difficult-to-treat #Cancers - pancreatic, bladder, breast, head and neck, and colorectal cancers - using 3T’s best-in-class #3T-TRACE target discovery platform. Read more here https://bit.ly/4c6iHeD

We're #hiring!

At 3T every one of us is committed to helping patients live better and healthier lives through our development of next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases. Thank you to the team for all your hard work!   #employeeappreciationday #immunotherapy #biotech

Today, Boehringer Ingelheim and 3T Biosciences are pleased to announce a second partnership focused on discovering and developing next-generation #cancer #immunotherapies.    This new collaboration It brings together 3T’s best-in-class 3T-TRACE discovery platform with Boehringer Ingelheim’s commitment to develop first-in-class immuno-oncology treatments that boost the immune system’s ability to recognize, attack and kill tumors.   Read more about this collaboration in our press release: https://lnkd.in/griNxiqm